Last reviewed · How we verify

NCT05361447

Diazepam Trial in GAD65 Associated Epilepsy

Withdrawn Phase 1, PHASE2 Last updated 6 March 2025
What this trial tests

Phase 1, PHASE2 trial testing Diazepam in GAD 65 Antibody-associated Epilepsy. Withdrawn.

Timeline
11 January 2023
Primary endpoint
13 December 2024
13 December 2024

Quick facts

Lead sponsorMayo Clinic
PhasePhase 1, PHASE2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date11 January 2023
Primary completion13 December 2024
Estimated completion13 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with GAD 65 Antibody-associated Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether diazepam reduces the frequency of seizures in GAD65 antibody associated epilepsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Diazepam

Trials testing the same drug.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05361447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing